MedDataX Logo

Improvement in Baroreflex Sensitivity in OSAS

NCT ID: NCT00284037

Last Updated: 2006-01-31

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Study Classification

INTERVENTIONAL

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Individuals with obstructive sleep apnea syndrome (OSAS) are at high risk for cardiovascular morbidity and mortality. The effect of long-term nocturnal therapy with continuous positive airway pressure (CPAP) on daytime baroreflex sensitivity (BRS), a predictor of cardiac death, was investigated in OSAS patients.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Obstructive Sleep Apnea Syndrome

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

obstructive sleep apnea, baroreceptors

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

continuous positive airway pressure therapy

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* obstructive sleep apnea syndrome

Exclusion Criteria

* diabetes mellitus, chronic obstructive lung disease, coronary or valvular heart disease, congestive heart failure, renal failure, or endocrine dysfunction. Moreover, none of them were taking b-blockers, vasodilators, or inotropic agents at the time of enrollment in the study.
Minimum Eligible Age

20 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Nagoya University

OTHER

Sponsor Role lead

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Mitsuhiro Yokota, MD.PhD

Role: STUDY_CHAIR

Department of Cardiovascular Genome Science, Nagoya University School of Medicine, Nagoya, Aichi, Japan

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Nagoya University of Health Sciences

Nagoya, , Japan

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Japan

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Akiko Noda, PhD

Role: CONTACT

Phone: +81-52-719-1537

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Akiko Noda, PhD

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

NU-06-A-0003

Identifier Type: -

Identifier Source: org_study_id